suxamethonium Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
quaternary ammonium compounds 2489 306-40-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • suxamethonium chloride
  • succinylcholine
  • suxamethonium
  • dicholine succinate
  • succinic acid dicholine diester
  • succinocholine
  • succinoylcholine
  • succinylbischoline
  • succinylcholine chloride
A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.
  • Molecular weight: 290.40
  • Formula: C14H30N2O4
  • CLOGP: -6.87
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 0
  • TPSA: 52.60
  • ALOGS: -5.68
  • ROTB: 11

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Aug. 20, 1952 FDA SANDOZ

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 433.98 36.23 131 4030 20143 46661758
Cardiac arrest 186.85 36.23 110 4051 90289 46591612
Hyperthermia malignant 184.39 36.23 35 4126 714 46681187
Hypotension 181.82 36.23 156 4005 232433 46449468
Exposure during pregnancy 163.72 36.23 108 4053 108104 46573797
Diabetes insipidus 152.44 36.23 36 4125 2138 46679763
Anaphylactic reaction 134.77 36.23 74 4087 53038 46628863
Bronchospasm 134.06 36.23 51 4110 15656 46666245
Maternal exposure during pregnancy 116.64 36.23 86 4075 102463 46579438
Renal ischaemia 116.48 36.23 23 4138 580 46681321
PCO2 increased 110.44 36.23 25 4136 1229 46680672
PO2 increased 96.29 36.23 21 4140 869 46681032
Foetal death 87.78 36.23 32 4129 8711 46673190
Blood pH decreased 87.42 36.23 24 4137 2603 46679298
Oxygen saturation abnormal 86.61 36.23 24 4137 2694 46679207
Blood bicarbonate decreased 80.67 36.23 23 4138 2862 46679039
Neuromuscular block prolonged 76.81 36.23 16 4145 530 46681371
Ventricular tachycardia 76.61 36.23 35 4126 16932 46664969
Delayed recovery from anaesthesia 74.92 36.23 17 4144 844 46681057
Rhabdomyolysis 73.45 36.23 46 4115 41863 46640038
Left ventricular dysfunction 72.27 36.23 29 4132 10226 46671675
Bradycardia 71.66 36.23 54 4107 66244 46615657
Foetal exposure during pregnancy 67.46 36.23 39 4122 30708 46651193
Pulseless electrical activity 67.39 36.23 25 4136 7142 46674759
Apnoea 59.59 36.23 23 4138 7316 46674585
Status epilepticus 57.38 36.23 27 4134 13952 46667949
Drug interaction 54.47 36.23 78 4083 203016 46478885
Anaesthetic complication 53.12 36.23 15 4146 1802 46680099
Renal impairment 51.89 36.23 47 4114 74325 46607576
Premature baby 50.75 36.23 27 4134 18085 46663816
Blood magnesium decreased 50.63 36.23 23 4138 10969 46670932
Electroencephalogram abnormal 50.15 36.23 17 4144 3737 46678164
Patent ductus arteriosus 49.67 36.23 17 4144 3845 46678056
Kounis syndrome 49.51 36.23 13 4148 1189 46680712
Encephalopathy 46.91 36.23 32 4129 33557 46648344
Ventricular fibrillation 46.55 36.23 22 4139 11474 46670427
Clonus 44.94 36.23 16 4145 4064 46677837
Hyperkalaemia 43.34 36.23 36 4125 50673 46631228
Blood calcium decreased 42.88 36.23 23 4138 15650 46666251
Maternal exposure during delivery 39.32 36.23 10 4151 806 46681095
Diarrhoea 38.71 36.23 3 4158 559599 46122302
Seizure 38.54 36.23 51 4110 123003 46558898
Unresponsive to stimuli 36.48 36.23 27 4134 32147 46649754

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperthermia malignant 335.27 34.29 68 2925 1766 29947719
Anaphylactic shock 238.06 34.29 78 2915 13915 29935570
Anaphylactic reaction 146.12 34.29 66 2927 27916 29921569
Serotonin syndrome 139.17 34.29 56 2937 17835 29931650
Cardiac arrest 104.66 34.29 81 2912 92769 29856716
Bronchospasm 75.63 34.29 31 2962 10307 29939178
Anaesthetic complication 69.34 34.29 17 2976 1052 29948433
Rhabdomyolysis 68.30 34.29 54 2939 63526 29885959
Procedural hypotension 64.96 34.29 16 2977 1009 29948476
Seizure like phenomena 58.14 34.29 13 2980 537 29948948
Pseudocholinesterase deficiency 54.87 34.29 8 2985 23 29949462
Neuromuscular block prolonged 51.74 34.29 11 2982 358 29949127
Metabolic acidosis 51.69 34.29 37 2956 37424 29912061
Hypotension 51.39 34.29 80 2913 200485 29749000
Ventricular tachycardia 51.04 34.29 31 2962 23831 29925654
Blood creatine phosphokinase increased 48.66 34.29 38 2955 43810 29905675
Muscle rigidity 46.55 34.29 22 2971 10239 29939246
Apnoea 43.15 34.29 18 2975 6240 29943245
Pseudomonal sepsis 40.14 34.29 14 2979 2986 29946499
Methaemoglobinaemia 38.60 34.29 13 2980 2497 29946988
Drug interaction 34.51 34.29 67 2926 199501 29749984

Pharmacologic Action:

SourceCodeDescription
ATC M03AB01 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
Choline derivatives
FDA EPC N0000175719 Depolarizing Neuromuscular Blocker
FDA PE N0000175733 Neuromuscular Depolarizing Blockade
MeSH PA D009465 Neuromuscular Agents
MeSH PA D009466 Neuromuscular Blocking Agents
MeSH PA D009467 Neuromuscular Depolarizing Agents
MeSH PA D018373 Peripheral Nervous System Agents
CHEBI has role CHEBI:51371 muscle relaxants
CHEBI has role CHEBI:88188 allergenic drug

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Muscle relaxation, function indication 11977004
General anesthesia indication 50697003
Skeletal Muscle Relaxation for Endotracheal Intubation indication
Ocular hypertension contraindication 4210003 DOID:9282
Hypocalcemia contraindication 5291005
Poisoning by digitalis glycoside contraindication 12876009
Hyperkalemia contraindication 14140009
Glaucoma contraindication 23986001 DOID:1686
Infectious disease contraindication 40733004
Myxedema contraindication 43153006 DOID:11634
Hypokalemia contraindication 43339004
Burn injury contraindication 48333001
Bradycardia contraindication 48867003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Muscular dystrophy contraindication 73297009 DOID:9884
Duchenne muscular dystrophy contraindication 76670001 DOID:11723
Third degree burn injury contraindication 80247002
Spinal cord injury contraindication 90584004
Myasthenia gravis contraindication 91637004 DOID:437
Fracture of bone contraindication 125605004
Disorder of muscle contraindication 129565002 DOID:423
Spasticity contraindication 221360009
Rhabdomyolysis contraindication 240131006
Anemia contraindication 271737000 DOID:2355
Injury of eye region contraindication 282752000
Deficiency of cholinesterase contraindication 360607009
At risk for aspiration contraindication 371736008
Primary malignant neoplasm contraindication 372087000
Surgical procedure on eye proper contraindication 373353005
Fever contraindication 386661006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Malignant hyperthermia contraindication 405501007
Cardiac arrest contraindication 410429000 DOID:0060319
Traumatic injury contraindication 417746004
Cardiac Decompensation contraindication

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscle-type nicotinic acetylcholine receptor Ion channel AGONIST CHEMBL CHEMBL
Acetylcholinesterase Enzyme Ki 4.68 CHEMBL

External reference:

IDSource
4017730 VUID
N0000178917 NUI
D00766 KEGG_DRUG
71-27-2 SECONDARY_CAS_RN
4017730 VANDF
4019935 VANDF
C0038627 UMLSCUI
CHEBI:45652 CHEBI
SCK PDB_CHEM_ID
CHEMBL703 ChEMBL_ID
CHEMBL983 ChEMBL_ID
DB00202 DRUGBANK_ID
D013390 MESH_DESCRIPTOR_UI
5314 PUBCHEM_CID
4004 IUPHAR_LIGAND_ID
26 INN_ID
J2R869A8YF UNII
10154 RXNORM
1940 MMSL
5517 MMSL
d00376 MMSL
001676 NDDF
005590 NDDF
372724004 SNOMEDCT_US
3822002 SNOMEDCT_US
58907007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
QUELICIN Human prescription drug label 1 0409-6629 INJECTION, SOLUTION 20 mg INTRAMUSCULAR NDA 13 sections
QUELICIN Human prescription drug label 1 0409-6629 INJECTION, SOLUTION 20 mg INTRAMUSCULAR NDA 13 sections
QUELICIN Human prescription drug label 1 0409-6629 INJECTION, SOLUTION 20 mg INTRAMUSCULAR NDA 13 sections
QUELICIN Human prescription drug label 1 0409-6970 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 13 sections
QUELICIN Human prescription drug label 1 0409-6970 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 13 sections
Anectine HUMAN PRESCRIPTION DRUG LABEL 1 0781-3009 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 23 sections
Anectine HUMAN PRESCRIPTION DRUG LABEL 1 0781-3411 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 20 sections
Anectine HUMAN PRESCRIPTION DRUG LABEL 1 0781-9053 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 20 sections
Succinylcholine Chloride Human Prescription Drug Label 1 14445-407 INJECTION 20 mg INTRAVENOUS ANDA 22 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 14789-104 INJECTION 20 mg INTRAVENOUS ANDA 21 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-493 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 13 sections
Succinylcholine Chloride Human Prescription Drug Label 1 31722-981 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 21 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 42571-371 INJECTION 200 mg INTRAMUSCULAR ANDA 21 sections
Succinylcholine HUMAN PRESCRIPTION DRUG LABEL 1 43598-666 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 20 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 49396-0152 INJECTION 200 mg PARENTERAL ANDA 2 sections
SUCCINYLCHOLINE CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1353 INJECTION, SOLUTION 20 mg INTRAMUSCULAR NDA 13 sections
SUCCINYLCHOLINE CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1525 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 12 sections
SUCCINYLCHOLINE CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1526 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 13 sections
SUCCINYLCHOLINE CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51991-964 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 22 sections
SUCCINYLCHOLINE CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 52584-097 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 12 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 52584-964 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 13 sections
Succinylcholine Chloride Human prescription drug label 1 52817-734 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 22 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 54879-037 INJECTION 20 mg INTRAVENOUS ANDA 22 sections
SUCCINYLCHOLINE CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 63323-943 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 22 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 66794-232 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 13 sections
SUCCINYLCHOLINE CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 68001-448 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 20 sections
Succinylcholine Chloride Human Prescription Drug Label 1 68083-450 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 12 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 69918-700 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 20 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 69918-700 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 20 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 70069-301 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 12 sections